Analysis of Epirubicin in Treating Non-muscle Invasive Bladder Tumors: Retrospective Descriptive Analysis, Monocentric Study

Moussaab Rachid, Ghassane El Omri, Taghouan Anas, Raiis Hamza, Boularbah Karim, Younes Houry and Abdeljalil Heddat
Additional contact information
Moussaab Rachid: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco
Ghassane El Omri: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco
Taghouan Anas: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco
Raiis Hamza: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco
Boularbah Karim: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco
Younes Houry: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco
Abdeljalil Heddat: Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco

European Journal of Medical and Health Sciences, 2025, vol. 7, issue 2, 19-22

Abstract: Purpose: BCG and MMC are the most popular drugs for adjuvant intravesical instillations in Non-Muscle-Invasive Bladder Cancer (NMIBC). In recent years, there has been a risk of shortage of these two agents worldwide. For this reason, our study aims to determine the characteristics of NMIBC in our department and the results following their treatment with Epirubicin. Methods: This inquiry is a retrospective descriptive study of 09 patients regrouped from the Urology Department of Cheikh Khalifa Hospital. Results: The results obtained revealed a predominance of low-grade urothelial carcinomas with an intermediate risk of recurrence and progression. Intravesical instillations of Epirubicin have shown a recurrence rate of 44.44% and a progression rate of 33.33%, with local side effects observed in 5 patients. Conclusion: Despite the limited number of patients in our study, treatment with Epirubicin has demonstrated therapeutic efficacity, approaching that of BCG and MMC, with an acceptable toxic profile.

Keywords: Epirubicin; non-muscle invasive bladder tumors (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/ejmed/article/view/42101 Abstract page (text/html)
https://eu-opensci.org/index.php/ejmed/article/download/42101/10654 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:ejmed0:v:7:y:2025:i:2:id:42101

DOI: 10.24018/ejmed.2025.7.2.2101

Access Statistics for this article

More articles in European Journal of Medical and Health Sciences from European Open Science
Bibliographic data for series maintained by Support ().